|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
Ra Pharmaceuticals Inc (RARX)
DAILY VOLUME INDEX
Trading: SELL @ $46.9
Signal Strength: MEDIUM
Ra Pharmaceuticals Inc (NASDAQ:RARX) current distribution has given weakness to the share price and the continuation of bearish trading conditions. Currently, the DVI is -34.
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading exit. Indicator can be applied to the short/medium term timeframe, but the best results are obtained with larger cyclical swings in-line with the trend direction. This accumulation / distribution oscillator can provide guidance on the money flow direction from the companies recent trading.
The daily volume index (DVI) is the amount of individual securities traded in a day on average over a specified period of time. Trading activity relates to the liquidity of a security. When average daily trading volume is high the stock can be easily traded and has high liquidity if trading volume is not very high and the security will tend to be less expensive because people are not as willing to buy it. As a result average daily trading volume can have an effect on the price of the security.
Calculation: Daily Volume Index (DVI):
1) [Close]-[Average price] / [Average price] x [Volume];
PROFILE: Ra Pharmaceuticals Inc (RARX)
Stock Exchange: NASDAQ
Company: Ra Pharmaceuticals Inc
Ticker Codes: | RARX | NASDAQ:RARX |
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.
|FARM Farmer Brothers||13.38||4.4||116,584||-129||BEARISH|
|TRUP Trupanion Inc||33.32||4.2||261,897||-1,829||BEARISH|
|MESO Mesoblast Ads||9.99||4.1||130,699||-319||BEARISH|
|BCOR Blucora Inc||23.41||3.2||401,986||-661||BEARISH|
|VSEC VSE Corporation||34.74||3||14,243||-30||BEARISH|
|VRAY Viewray Inc||3.06||3||3,697,594||-63,899||BEARISH|
|NTLA Intellia Therapeutics||14.64||1.9||548,959||-1,650||BEARISH|
|ATRI Atrion Corp||748.12||1.8||6,370||-4||BEARISH|